Retatrutide Research Peptide UK

Why can’t I order GLP-1 products via the website?

Due to online platform restrictions, GLP-1 compounds cannot be purchased directly through our standard website checkout. All GLP-1 orders are therefore processed manually via WhatsApp, with secure payment arranged through Open Banking. Once confirmed, UK orders are dispatched via Royal Mail Tracked 24, providing a fast and fully tracked delivery service.

Retatrutide Price UK

Our current Retatrutide research range:

Retatrutide 10mg — £60
Retatrutide 20mg — £100
Retatrutide 30mg — £140

To order or check current availability, contact Axiom Labs UK via WhatsApp.

Prices and availability may change.

What Is Retatrutide?

Retatrutide is an investigational peptide being studied for its activity across three important metabolic receptor pathways.

Unlike compounds that target GLP-1 alone, Retatrutide acts as a triple-receptor agonist, targeting:

GLP-1 (glucagon-like peptide-1) receptors
GIP (glucose-dependent insulinotropic polypeptide) receptors
Glucagon receptors

This combined GLP-1 + GIP + glucagon receptor activity has made Retatrutide an important subject within current metabolic and incretin research.

Retatrutide remains an investigational compound and research into its efficacy, safety and wider metabolic effects is ongoing.

How Does Retatrutide Work?

Retatrutide is particularly interesting to researchers because a single peptide has been engineered to activate three different receptor systems.

Each pathway has a different physiological role.

GLP-1 Receptor Activity

GLP-1 is an incretin hormone involved in several metabolic processes.

GLP-1 receptor signalling has been extensively researched in relation to:

Glucose-dependent insulin secretion
Appetite signalling
Satiety
Gastric emptying
Glucose regulation

GIP Receptor Activity

GIP is another naturally occurring incretin hormone.

It is released primarily in response to nutrient intake and has an important role in glucose-dependent insulin signalling and energy metabolism.

Combining GIP and GLP-1 receptor activity has become an increasingly important area of metabolic research.

Glucagon Receptor Activity

The addition of glucagon receptor agonism is one of the characteristics that distinguishes Retatrutide from GLP-1-only and dual GLP-1/GIP compounds.

Glucagon plays an important role in glucose regulation and energy metabolism.

Researchers are investigating how combining glucagon receptor activity with GLP-1 and GIP signalling may influence energy expenditure, substrate utilisation and overall metabolic regulation.

Why Is Retatrutide Called a Triple-Receptor Agonist?

The term triple-receptor agonist refers to Retatrutide's activity across three receptor pathways:

GLP-1 + GIP + Glucagon

This differs from several other metabolic research compounds:

Semaglutide: GLP-1
Tirzepatide: GLP-1 + GIP
Mazdutide: GLP-1 + Glucagon
Retatrutide: GLP-1 + GIP + Glucagon

The addition of a third receptor pathway is one reason Retatrutide has attracted significant interest within next-generation metabolic research.

Retatrutide Research

Retatrutide has been investigated in clinical research examining obesity and metabolic health.

Clinical research has examined outcomes including:

Body-weight changes
Waist circumference
Glucose regulation
Insulin and A1C
Lipid measurements
Blood pressure
Cardiometabolic outcomes
Safety and tolerability

Phase 2 research demonstrated substantial changes in body weight over 48 weeks, supporting further clinical development.

Retatrutide has since progressed into an extensive Phase 3 clinical research programme investigating obesity, type 2 diabetes and several obesity-associated conditions.

It is important to distinguish clinical research findings from regulatory approval. Retatrutide remains investigational.

Retatrutide and Metabolic Research

Modern metabolic peptide research is increasingly moving beyond compounds that activate a single receptor.

Scientists are investigating whether simultaneously targeting multiple metabolic signalling pathways can produce different biological responses compared with single-receptor activation.

Retatrutide provides researchers with the opportunity to investigate interactions between:

GLP-1 incretin signalling

GIP incretin signalling

Glucagon receptor signalling

Areas of scientific interest include appetite regulation, energy balance, glucose metabolism and broader cardiometabolic markers.

Retatrutide vs Tirzepatide

Retatrutide and Tirzepatide share activity at two receptors but have different receptor profiles.

Tirzepatide:
GIP + GLP-1

Retatrutide:
GIP + GLP-1 + Glucagon

The major distinction is the additional glucagon receptor activity of Retatrutide.

Retatrutide vs Semaglutide

Semaglutide primarily targets the GLP-1 receptor.

Retatrutide targets three receptor systems:

GLP-1 + GIP + Glucagon

The compounds therefore have substantially different receptor profiles despite both involving GLP-1 signalling.

Current Retatrutide Research Status

Retatrutide remains an investigational compound undergoing clinical development.

It has not received general regulatory approval, and ongoing research continues to investigate its efficacy, safety profile and potential medical applications.

Frequently Asked Questions About Retatrutide

What is Retatrutide?

Retatrutide is an investigational peptide with activity at the GLP-1, GIP and glucagon receptors, commonly described as a triple-receptor agonist.

Is Retatrutide a GLP-1?

Retatrutide has GLP-1 receptor agonist activity, but its activity is not limited to GLP-1. It also targets GIP and glucagon receptors.

What is the difference between Retatrutide and Tirzepatide?

Tirzepatide targets GIP and GLP-1 receptors, whereas Retatrutide additionally targets the glucagon receptor.

What is the difference between Retatrutide and Semaglutide?

Semaglutide is a GLP-1 receptor agonist. Retatrutide combines GLP-1, GIP and glucagon receptor agonism within a single investigational molecule.

Is Retatrutide approved?

No. Retatrutide remains an investigational compound undergoing clinical development.

What is Retatrutide being researched for?

Clinical research has investigated Retatrutide across obesity, body-weight regulation, type 2 diabetes and other metabolic and cardiometabolic outcomes.